Myriad Genetics, Inc. (MYGN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$6.29+4.49%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · MYGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 32.7% |
| Our one-year growth estimate | diamond | 4.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 28.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 18 industry peers · Company calendar date is not available
MYGN — litigation filed
Dated 2026-11-05
Other Events On November 2, 2026, Myriad Genetics, Inc. (the “Company”) detected unauthorized access within its information technology network environment. Upon discovery, the Company promptly initiated its incident response procedures to contain the activity, assess and investigate the nature and scope of the incident, and implement appropriate remedial measures, including temporarily suspending its testing operations and order management systems and resetting certain system credentials. The…
Why it matters: Average revenue per test fell 9% in Q2. Myriad tied the pressure to payer friction and called it a top priority.
Watch forQ3 average revenue per test is flat or higher year over year. No new large adjustment lowers past-period collections.
Also watch forQ3 average revenue per test falls more than 9% year over year. Or Myriad reports another large cut tied to past collections.
Why it matters: Q2 revenue fell 11% year over year, and Myriad cut its 2026 revenue range to $770–$790 million. Q3 results will show if the decline is easing.
Watch forQ3 revenue is at least $190.7 million, and management keeps or raises the $770–$790 million 2026 range.
Also watch forQ3 revenue is below $190.7 million, or management cuts the 2026 revenue range below $770 million.
Why it matters: Cancer Care Continuum volume grew 6% in Q2, but revenue fell 11%. A sale of prenatal testing puts more focus on cancer tests.
Watch forCancer Care Continuum volume grows year over year and its revenue decline is smaller than Q2's 11% drop.
Also watch forCancer Care Continuum volume falls year over year, or revenue falls 11% or more year over year again.
Why it matters: The $210 million cash sale would bring funds to Myriad and remove a business with falling sales. The deal still needs regulatory clearance and other closing steps.
Watch forMyriad and Labcorp report that the sale closed by early 2027 for $210 million plus inventory value.
Also watch forThe companies report a failed deal, a material delay beyond early 2027, or a lower cash price than $210 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$235 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $617 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,384 loss on $10,000 · 63.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.